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Adoptive cellular therapy (ACT) of cancer usingﾭ 
in vitro differentiated CD8+ T cells is a power­
ful treatment agﾭainst established cancer in humans 
and mice. In recent years, gﾭreat progﾭress has 
been  attained  in  the  understandingﾭ  of  the 
mechanisms involved in enhancingﾭ treatment 
of largﾭe established tumors (Gattinoni et al., 
2006). Lymphodepletion before adoptive ther­
apy gﾭreatly enhances ACT in humans and mice 
througﾭh the creation of cytokine sinks, removal 
of regﾭulatory T cells (T regﾭ cells), and the re­
lease of toll­like receptor agﾭonists (Gattinoni   
et al., 2005a; Paulos et al., 2007; Dudley et al., 
2008). Recent evidence sugﾭgﾭests that irradia­
tion also enhances the expression of ICAM and 
VCAM in the tumor vasculature allowingﾭ tu­
mor­reactive  T  cells  to  enter  more  readily 
(Quezada et al., 2008). Althougﾭh CD8+ T cells 
are potent mediators of antitumor immunity, 
there has been little focus on tumor­specific 
CD4+ T cells. CD4+ Th cells are important in 
immunity because in the absence of help, CD8+ 
T cells can be deleted or lose the capacity to 
develop into memory CD8+ T cells upon re­
challengﾭe (Janssen et al., 2003; Antony et al., 
2005; Williams et al., 2006). Therefore, the use 
of tumor/self­reactive CD8+ T cells in the 
adoptive immunotherapy of cancer may face 
similar fates because T cells must remove tumor 
antigﾭen in the context of persistingﾭ self­antigﾭen, 
which  in  some  cases  leads  to  autoimmunity 
(Gattinoni et al., 2006; Rosenbergﾭ et al., 2008). 
Adoptive cell therapies that incorporate CD4+  
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In vitro differentiated CD8+ T cells have been the primary focus of immunotherapy of cancer 
with little focus on CD4+ T cells. Immunotherapy involving in vitro differentiated T cells 
given after lymphodepleting regimens significantly augments antitumor immunity in animals 
and human patients with cancer. However, the mechanisms by which lymphopenia augments 
adoptive cell therapy and the means of properly differentiating T cells in vitro are still 
emerging. We demonstrate that naive tumor/self-specific CD4+ T cells naturally differenti-
ated into T helper type 1 cytotoxic T cells in vivo and caused the regression of established 
tumors and depigmentation in lymphopenic hosts. Therapy was independent of vaccination, 
exogenous cytokine support, CD8+, B, natural killer (NK), and NKT cells. Proper activation  
of CD4+ T cells in vivo was important for tumor clearance, as naive tumor-specific CD4+  
T cells could not completely treat tumor in lymphopenic common gamma chain (c)–deficient 
hosts. c signaling in the tumor-bearing host was important for survival and proper differ-
entiation of adoptively transferred tumor-specific CD4+ T cells. Thus, these data provide a 
platform for designing immunotherapies that incorporate tumor/self-reactive CD4+ T cells.
© 2010 Xie et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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is expressed in maligﾭnant melanoma and in the skin and eyes 
of mice and humans; therefore, this model mimics the human 
condition as closely as possible. Surprisingﾭly, we found that 
adoptive transfer of naive TRP­1–specific CD4+ T cells into 
lymphopenic  animals  bearingﾭ  largﾭe  established  melanoma 
caused tumor regﾭression and depigﾭmentation independent of 
vaccination, cytokine administration, and CD8+, B, NK, and 
NKT cells. This therapy was dependent on common gﾭamma 
chain (c) sigﾭnalingﾭ in the host for survival and differentiation 
of CD4+ T cells in vivo. These data provide a better under­
standingﾭ for the desigﾭn of immunotherapies that incorporate 
tumor/self­reactive CD4+ T cells.
RESULTS
Autoimmunity and cancer regression with adoptive transfer 
of naive tumor-specific TRP-1 CD4+ T cells into lymphopenic 
mice TRP­1–specific CD4+ TCR Tgﾭ mice were created on 
a C57BL/6 backgﾭround that contains TRP­1 as a self­antigﾭen 
(Muranski et al., 2008). These mice develop vitiligﾭo (depigﾭ­
mentation) slowly with agﾭe (Figﾭ. S1 A) but can develop vitiligﾭo 
rapidly with gﾭenetic removal of Foxp3 (denoted Foxp3sf), 
which is required for development of T regﾭ cells that suppress 
autoimmune disease (Kim et al., 2007; Figﾭ. 1 A and Figﾭ. S1 B). 
TRP­1–specific CD4+ TCR Tgﾭ mice, which express TRP­1 
antigﾭen, have activated T cells that are characterized by low 
expression of CD62L and higﾭh expression of CD44 on TRP­1 
CD4+ T cells in vivo (Figﾭ. S1 C, top). Because we wanted to 
study naive CD4+ T cells, Tyrp1+/+ TRP­1 CD4+ Tgﾭ mice 
were crossed with white­based brown mutation mice (Tyrp1B-w) 
containingﾭ a radiation­induced inversion interruptingﾭ the tyrp1 
gﾭene (Smyth et al., 2006). RT­PCR confirmed that no Tyrp1 
messengﾭer RNA (mRNA) was present in Tyrp1B-w mice, and 
Tyrp1B-w  mice  that  express  the  Tgﾭ  TCR  do  not  develop 
vitiligﾭo (unpublished data). These mice have a ligﾭht­brown 
coat color (Figﾭ. S1 D) and were further crossed with RAG/ 
mice to gﾭenerate naive monoclonal TRP­1–specific CD4+ T 
cells (Figﾭ. S1 C, bottom). This mouse model is unique in 
that it develops T cells specific for TRP­1 that are both 
Foxp3 and Foxp3+ on a RAG/ backgﾭround. The ex­
pression of Foxp3 is at the natural physiologﾭical ratio of 
5–15% (Figﾭ. S1 E).
Once TRP­1–specific CD4+ TCR Tgﾭ mice on a Tyrp1B-w­
RAG/ backgﾭround were obtained (hereafter denoted as 
TRP­1 CD4+ T cells), TRP­1 CD4+ T cells were transferred 
into nontumor­bearingﾭ RAG/ mice and observed for sigﾭns 
of specific immunity (e.gﾭ., depigﾭmentation). Indeed, 5–6 wk 
after transfer, the mice developed progﾭressive depigﾭmenta­
tion as indicated by coat color changﾭes from black to white 
(Figﾭ. 1 B). Depigﾭmentation progﾭressed until the mice became 
completely white.
To determine if adoptive transfer of TRP­1 CD4+ T cells 
could  mediate  the  regﾭression  of  established  tumors,  WT, 
RAG/, and irradiated WT mice (5 Gy) were gﾭiven 2 × 105 
B16 tumor cells s.c. On day 7, after tumor was visible and 
  palpable, sorted TRP­1 CD4+ T cells from 2 × 105 Tyrp1B-w­
RAG/ mice were transferred i.v. by tail vein injection into   
T cells are far superior to therapies that only use CD8+ T   
cell clones (Dudley et al., 2002). Therefore, one theoretical 
means  of  improvingﾭ  immunotherapy  to  self  may  involve   
the provision of tumor­reactive or self­reactive CD4+ T cells 
(Nishimura et al., 1999; Marzo et al., 2000; Antony et al., 2005), 
but a more direct role for CD4+ T cells in tumor immunity   
remains unclear (Ho et al., 2002; Muranski and Restifo, 2009).
Recently,  adoptive  transfer  of  in  vitro  differentiated   
tumor­specific CD4+ T cells in humans and mice has shown 
promise agﾭainst cancer as a therapy (Nishimura et al., 1999; 
Perez­Diez et al., 2007; Hunder et al., 2008; Muranski et al., 
2008). This has rekindled the idea of usingﾭ antigﾭen­specific 
CD4+ Th duringﾭ immunotherapy because CD4+ Th cells can 
mediate the proper sigﾭnals required in vivo to activate CD8+ 
T cells and other cells of the innate immune system (Kahn   
et al., 1991; Hungﾭ et al., 1998; Nishimura et al., 1999; Antony 
et al., 2006; Williams et al., 2006). In fact, several preclinical 
and clinical trials have shown the importance of CD4 help 
duringﾭ immunotherapy of cancer (Nishimura et al., 1999; 
Antony et al., 2006; Dudley et al., 2008). However, isolation 
of  tumor­specific  CD4+  T  cells  has  been  difficult  (Wangﾭ, 
2001) and only a few MHC class II vaccines have been pro­
duced as a result of the lack of knowledgﾭe of how to gﾭenerate 
vaccines that specifically activate Th cells instead of tumor­
specific Foxp3+ T regﾭ cells (Rosenbergﾭ, 2001; Vence et al., 
2007). In addition, lack of appropriate mouse models to study 
tumor­specific CD4+ T cell responses to self­antigﾭens has hin­
dered progﾭress in our understandingﾭ of the role of CD4+ T 
cells in maintainingﾭ immunity to cancer.
Now, with a better understandingﾭ of CD4+ T cell biol­
ogﾭy, the use of cytokines to differentiate and expand T cells 
in vitro has led to a panoply of CD4 lineagﾭes with specific in 
vivo functions (Weaver and Rudensky, 2009). For example, 
in  vitro  differentiated  CD4+  Th17  tumor­specific  T  cells 
have shown superiority over CD4+ Th1 differentiated T cells 
in the adoptive immunotherapy of cancer in a mouse model 
of melanoma (Muranski et al., 2008). IL­2 and IL­7 in vitro 
expanded NY­ESO­1–specific CD4+ T cells in humans have 
also  shown  clinical  promise  in  one  patient  who  had  not   
received prior lymphodepletingﾭ conditioningﾭ or a vaccine 
(Hunder et al., 2008). Althougﾭh these are promisingﾭ studies, 
the mechanisms involved in the direct therapy of cancer by 
CD4+ T cells remain elusive. Likewise, methods for enhanc­
ingﾭ adoptive immunotherapy without prior in vitro manipu­
lation that may lead to the terminal differentiation of T cells 
also remain unclear (Gattinoni et al., 2005b, 2009; Klebanoff 
et  al.,  2005).  Althougﾭh  such  manipulations  can  lead  to   
vaccine  independence  (Klebanoff  et  al.,  2009),  longﾭ­term 
benefits from in vivo differentiation may outweigﾭh in vitro 
stimulation because the in vivo environment may provide 
the correct sigﾭnals that cannot be attained in a culture dish.
To test a direct role for CD4+ T cells in the immuno­
therapy of cancer, we used a gﾭp75/tyrosinase­related protein 
(TRP) 1–specific CD4+ TCR transgﾭenic (Tgﾭ) mouse that 
produces  class  II–restricted  T  cells  that  recogﾭnize  mouse 
TRP­1 in the context of I­Ab (Muranski et al., 2008). TRP­1 JEM VOL. 207, March 15, 2010 
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Figure 1.  Treatment of established melanoma with adoptive transfer of TRP-1 CD4+ T cells into lymphopenic mice is specific. (A) Enhanced 
specific autoimmune disease in TRP-1 CD4+ Foxp3sf (Foxp3 negative) mice. TRP-1 CD4+ WT Tg mice (left; n = 13) and TRP-1 CD4+ Foxp3sf mice (right; n = 7) 
were compared for incidence of depigmentation over time. 1-mo-old littermates are shown. TRP-1 CD4+ Foxp3sf mice have no Foxp3+ T cells as shown by 
flow cytometry. (B) Depigmentation (vitiligo) can be adoptively transferred to lymphopenic hosts through TRP-1–specific CD4+ T cells. 2 × 105 TRP-1 CD4+  
T cells from Tyrp1B-wRAG/ mice were transferred to nontumor-bearing RAG/ hosts. Mice (n = 20) developed depigmentation after 35–45 d. A represen-
tative picture is shown. (C) Tumor-bearing WT mice were irradiated with 500 rads (5 Gy) or not irradiated (0 Gy) on day 7 after tumor challenge, and 2 × 105 
naive TRP-1 CD4+ T cells were adoptively transferred by i.v. tail vein injection. Experiments were repeated two times. P < 0.0001 for WT mice receiving 5 Gy 
and TRP-1 CD4+ T cells versus no treatment. (D) Tumor-bearing RAG/ mice were irradiated with 500 rads (5 Gy) or not irradiated (0 Gy) on day 7 after 
tumor challenge, and 2 × 105 naive TRP-1 CD4+ T cells were adoptively transferred by i.v. tail vein injection. Experiments were repeated nine times.  
P < 0.0001 for RAG/ no treatment versus RAG/ + TRP-1 CD4+ T cells (0 Gy or 5 Gy). (E) Whole body vitiligo in tumor-bearing mice treated with TRP-1 
CD4+ T cells (n = 40 mice). (F) Tumor regression in lymphopenic mice treated with TRP-1 CD4+ T cells at days 10 and 49. The picture is representative of  
40 mice over eight different experiments. (G) Adoptive transfer of 106 open repertoire CD4+CD25 T cells into lymphopenic tumor-bearing RAG/ mice on day 
7 after tumor challenge does not affect tumor growth. Data represent three independent experiments. n = 5 mice/group; P = NS. Error bars indicate SEM.
tumor­bearingﾭ  mice.  Adoptive  transfer  of  TRP­1  CD4+  
T cells into lymphopenic mice caused infiltration of tumor­
specific  T  cells  into  and  regﾭression  of  established  tumors   
(Figﾭ. 1, C and D; and Figﾭ. S1 F). Irradiated WT mice had a 
transient antitumor response, indicatingﾭ a temporary lym­
phodepletion as seen in mice and patients that are lympho­
depleted (Dudley et al., 2005; Gattinoni et al., 2005a; Zhangﾭ   
et al., 2005).
Because we wanted to study the role of CD4+ T cells in 
tumor  immunity,  we  focused  on  RAG/  mice  because 
these mice contain no CD8+ T cells, B cells, or NKT cells, all   
of which have been described in tumor immunity (Dougﾭan 
and Dranoff, 2009). Complete regﾭression of B16 melanoma 
was observed in RAG/ mice (Figﾭ. 1 D). RAG/ mice 
that received 5 Gy irradiation to deplete cytokine sinks 
(Gattinoni et al., 2005a) and adoptive cell transfer of TRP­1 654 Naive CD4+ T cells eradicate established melanoma | Xie et al.
Figure 2.  TRP-1 CD4+ T cells treating established tumors differentiate into Th1 CD4+ cytotoxic T cells in lymphopenic mice. (A) Gene expres-
sion analysis of TRP-1 CD4+ T cells from spleen and LNs of lymphopenic mice undergoing tumor regression. Heat maps represent fold changes in mRNA 
expression between naive TRP-1 CD4+ T cells and TRP-1 CD4+ T cells differentiated in vivo for 1 wk. The gene array is representative of one experiment.  
* indicates data confirmed by flow cytometry or multiplex assay. (B) IFN- levels in the serum of tumor-bearing WT and RAG/ mice with and without 
adoptive transfer of 2 × 105 TRP-1 CD4+ T cells 1 wk after transfer. Open circles represent individual mice receiving no treatment and closed circles repre-
sent individual mice receiving TRP-1 CD4+ T cells. Horizontal bars indicate means for treated groups only (n = 3–5 mice/group). Data are representative of JEM VOL. 207, March 15, 2010 
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three experiments (no treatment vs. treatment; P = 0.0047). (C) CXCR3 expression on naive TRP-1 CD4+ T cells before transfer (gray histogram) and 1 wk  
after in vivo differentiation (solid line). (D) ICOS expression on naive and 1wk in vivo differentiated TRP-1 CD4+ T cells. (E) Serum chemokines levels  
in WT and RAG/ mice treated or not (n = 3–5 mice/group). Open circles represent individual mice receiving no treatment and closed circles represent 
individual mice receiving TRP-1 CD4+ T cells. Horizontal bars indicate means for treated groups only. Data are representative of three experiments.
 
CD4+ T cells also had complete regﾭression. As seen in non­
tumor­bearingﾭ RAG/ mice, depigﾭmentation was present 
in tumor­bearingﾭ RAG/ mice at 5–wk after treatment 
(Figﾭ. 1 E). Tumor regﾭression was dramatic, with largﾭe estab­
lished tumors regﾭressingﾭ to a small scar (Figﾭ. 1 F). RAG/ 
mice do not have endogﾭenous CD8+ T, B, or NKT cells; 
therefore,  this  therapy  was  completely  independent  from 
these cell types. Because TRP­1 CD4+ T cells came from 
Tyrp1B-wRAG/ mice, there was no concern for contamina­
tion from other cells that may contribute to tumor therapy.
To determine whether tumor treatment in lymphopenic 
hosts was specific, we sorted “open­repertoire” CD4+CD25 
T cells from WT mice and transferred 106 CD4+ T cells into 
RAG/ mice on day 7 after tumor inoculation (Figﾭ. 1 G). 
CD4+CD25 T cells have virtually no Foxp3+ T cells and 
have been shown to help tumor­specific CD8+ T cells main­
tain treatment of established tumors without the addition of 
exogﾭenous  cytokines  (Antony  et  al.,  2006).  However,  by 
themselves,  CD4+CD25  open­repertoire  T  cells  did  not 
affect tumor gﾭrowth in lymphopenic mice. Therefore, we 
conclude that TRP­1 CD4+ T cells are specific for their   
tumor/self­antigﾭen in vivo and that the antitumor effect is 
independent of CD8+, B, and NKT cells.
TRP-1 CD4+ T cells differentiate into Th1 cytotoxic T cells 
in lymphopenic mice
Because it has been shown that in vitro differentiated Th17 
tumor­specific T cells were superior to other CD4+ T cell 
lineagﾭes when treatingﾭ established tumors (Muranski et al., 
2008), we wanted to determine the in vivo default differenti­
ation progﾭram that leads to strongﾭ tumor regﾭression by TRP­1 
CD4+ T cells. After 1 wk in vivo, adoptively transferred 
CD4+ T cells were FACS sorted from tumor­drainingﾭ LNs 
and the spleens of mice undergﾭoingﾭ tumor regﾭression and an­
alyzed by gﾭene microarray. These cells were compared with 
FACS­sorted naive TRP­1 CD4+ T cells. Only gﾭenes with a 
twofold or gﾭreater difference were displayed. As shown in 
Figﾭ. 2 A, TRP­1 CD4+ T cells transferred into a lymphope­
nic environment defaulted to a CD4+ Th1 progﾭram, as indi­
cated by higﾭh expression of Tbet, Ifng, Il18r, Il2r, Il12r (Th1 
primingﾭ), Il23r (Th1 memory; Robinson and O’Garra, 2002), 
Il27r  (early  Th1  primingﾭ),  Tim3,  Cxcr3,  Ccr2,  and  Ccr5 
mRNA, with evidence of some Th17­associated gﾭenes (Il22, 
Il23r, and Rora) and Th2 gﾭenes (Il10 and gata3) but not Ccr6, 
Il4, Il5, Il17a, Il17f, or Rorc. Genes for TCR sigﾭnalingﾭ were 
up­regﾭulated in the spleen (Lck and Zap70) but not in the 
LN, probably indicatingﾭ recently activated traffickingﾭ T cells, 
sugﾭgﾭested  by  increased  Cd69,  Cd5  (strongﾭ  TCR  sigﾭnals),   
and Lat expression. Jak3 was up­regﾭulated in TRP­1 T cells, 
indicatingﾭ  that  c  sigﾭnalingﾭ  was  active.  Stat4  was  higﾭhly   
expressed,  demonstratingﾭ  that  IL­12,  and  possibly  IL­23,   
sigﾭnals were potentiatingﾭ IFN­ production. Co­activation 
gﾭenes, includingﾭ 41BB and ICOS, were higﾭhly up­regﾭulated. 
Both  are  involved  in  enhancingﾭ  the  activation  of  T  cells 
(Tamada and Chen, 2006; Stephan et al., 2007; McNamara 
et al., 2008). Genes related to CTL effector functions were 
increased; Gzmb, Gzmc, Gzmd, and Gzmk were higﾭhly up­
regﾭulated, with only Gzmb and Gzmc stayingﾭ at higﾭh levels   
in the spleen. Fasl was also up­regﾭulated.
Genes that regﾭulate the expansion of T cells by control­
lingﾭ T cell activation in a negﾭative manner—TgfrI, Ctla-4, 
Cish, Il10, and Socs2—were also up­regﾭulated (Figﾭ. 2 A). 
Higﾭh IFN­ levels were confirmed in the serum of lympho­
penic mice undergﾭoingﾭ tumor treatment but not in WT mice 
or untreated lymphopenic RAG/ mice (Figﾭ. 2 B). CXCR3 
and ICOS, both Th1­associated molecules, were also expressed 
by TRP­1 CD4+ T cells (Figﾭ. 2, C and D).
Next, we looked at effector molecules in TRP­1 CD4+ T 
cells and found perforin, gﾭranzyme B, and LAMP­1 (CD107a), 
all of which are involved in degﾭranulatingﾭ cytotoxic T cells 
(Figﾭ. 3). Because TRP­1 CD4+ T cells expressed gﾭranzyme B 
on gﾭene array (Figﾭ. 2) and in the spleen (Figﾭ. 3), these data 
sugﾭgﾭest that the antitumor CD4+ T cells are cytotoxic. Thus, 
naive TRP­1 CD4+ T cells differentiated into a Th1 pheno­
type in vivo and expressed cytotoxic T cell–associated gﾭenes 
and molecules that may assist in antitumor immunity.
Adoptive transfer of naive TRP-1 CD4+ T cells into lymphopenic 
mice changes chemokine expression patterns
CXCR3, CCR2, and CCR5 are chemokine receptors that 
help draw Th1 CD4+ T cells into inflamed tissues. Because we 
saw higﾭh chemokine receptor expression on TRP­1 CD4+  
T cells (Figﾭ. 2, A and C), we checked the serum of lympho­
penic and nonlymphopenic mice for the specific ligﾭands   
and found higﾭh expression of IFN­–inducible CXCL9 and 
CXCL10 (the ligﾭands for CXCR3), as well as CCL2 (the 
ligﾭand for CCR2) and CCL11 (the ligﾭand for CCR2 and 
CCR5), in lymphopenic mice duringﾭ tumor regﾭression (Figﾭ. 
2 E). CCL3 (the ligﾭand for CCR5) was also moderately higﾭh 
in the serum of lymphopenic mice duringﾭ tumor regﾭression 
(unpublished results). CCL2 is known to draw inflammatory 
monocytes from the blood into LN and activate Th1 CD4+ 
T cells (Nakano et al., 2009). We saw accumulation of in­
flammatory monocytes (CD11bhigﾭhGR­1+) in the spleen, LN, 
and tumors of treated gﾭroups (Figﾭ. S2). These cells are class 
II+ and are known to secrete IFN­ that may help aid Th1 
differentiation (Nakano et al., 2009). Other chemokine re­
ceptors were up­regﾭulated on TRP­1 CD4+ T cells, includ­
ingﾭ CXCR6, which is involved in traffickingﾭ to the spleen, 
and CCR9 (Figﾭ. 2 A). Lastly, a multitude of inflammatory 656 Naive CD4+ T cells eradicate established melanoma | Xie et al.
no­treatment  gﾭroups  (Figﾭ.  4  B),  sugﾭgﾭestingﾭ,  as  previously 
shown, that MHC class II is needed to prime naive CD4+  
T cells (Beutner and MacDonald, 1998). This implies that 
MHC class II expression on the tumor was not sufficient to 
activate  naive  CD4+  T  cells.  However,  in  vitro  activated 
TRP­1 CD4+ T cells can treat MHC class II+ tumors in MHC 
class II/ mice, and anti­class II antibodies can block this ef­
fect (see Quezada et al. in this issue), showingﾭ that the func­
tion of activated CD4+ T cells is independent of host class II.
Next, to determine if tumor antigﾭen alone is enougﾭh to 
activate TRP­1 CD4+ T cells, tumor­bearingﾭ female Tyrp1B-w­
RAG/ mice, which express no TRP­1 antigﾭen, were trea­
ted with TRP­1 CD4+ T cells. In the absence of self­antigﾭen 
in the periphery, tumor treatment was complete and irradia­
tion did not affect the antitumor response (Figﾭ. 4 C). Even 
thougﾭh the tumor may be able to express class II, these ex­
periments demonstrate that T cell activation by host MHC 
class II+ cells may be essential for the success of treatment in 
the lymphopenic settingﾭ. These experiments also show that 
the tumor/self­antigﾭen, TRP­1, expressed only by the tumor, 
is adequate to activate naive TRP­1 CD4+ T cells trans­
ferred into Tyrp1B-wRAG/ mice.
IFN­ has been attributed to the mechanism of action by 
which CD4+ T cells eradicate tumors (Mumbergﾭ et al., 1999; 
Nishimura et al., 1999; Corthay et al., 2005; Muranski et al., 
2008).  We  administered  anti–IFN­  antibodies  (500  µgﾭ/
mouse) once, at the time of adoptive cell transfer, and found 
that anti–IFN­ antibodies were able to attenuate the anti­
tumor response in lymphopenic mice (Figﾭ. 4 D).
To determine why adoptive transfer of T cells resulted in 
activation of CD4+ T cells in RAG/ mice, we looked at 
CD11c+ DC activation status because these cells express higﾭh 
levels of MHC class II in vivo. We found, after adoptive cell 
transfer with TRP­1–specific CD4+ T cells, that CD11chigﾭh DC 
expressed  increased  levels  of  MHC  class  II  and  CD86 
chemokines were differentially expressed by TRP­1 CD4+ 
T cells in the LN and spleen (Figﾭ. 2 A). Therefore, TRP­1 
CD4+ T cells activated by lymphopenia­induced prolifera­
tion may help trigﾭgﾭer Th1 chemokines, which could enhance 
immunotherapy by recruitingﾭ inflammatory monocytes and 
CXCR3+CCR2+CCR5+ TRP­1 CD4+ T cells to appropri­
ate sites for activation and tumor infiltration.
Mechanisms of activation and effector function of TRP-1 
CD4+ T cells during lymphopenia
It is known that MHC class I is up­regﾭulated on tumor cells 
in vivo in the presence of IFN­+ tumor­specific CD8+ T cells   
(Palmer et al., 2008). However, it is not known whether 
IFN­ enhances MHC class II expression on established   
tumors in vivo. Because we saw higﾭh levels of IFN­ exp­
ression in the serum and on gﾭene microarray, we evaluated 
the expression of MHC class II in the tumor microenviron­
ment. 1 wk after adoptive transfer with TRP­1 CD4+ T cells, 
lymphopenic mice were sacrificed and tumors were imagﾭed 
for MHC class II expression by confocal microscopy. Lym­
phopenic mice that had received no TRP­1 CD4+ T cells 
had no evident expression of MHC class II on tumor cells in 
vivo. However, in mice that had received TRP­1 CD4+ T 
cells, MHC class II expression was higﾭhly expressed on tumor 
cells in vivo (Figﾭ. 4 A). To our knowledgﾭe, this is the first 
time class II up­regﾭulation in vivo by B16 melanoma has 
been reported. This may be similar to the mechanism of in­
duction of MHC class II reported in certain autoimmune 
diseases (Belfiore et al., 1991).
To determine if host MHC class II was important in   
activatingﾭ TRP­1 CD4+ T cells in mice with MHC class II+/+ 
tumors,  tumor­bearingﾭ  irradiated  and  nonirradiated  MHC 
class II/ mice were treated with naive TRP­1 CD4+ T cells. 
Mice were irradiated to mimic the lymphopenic environ­
ment. Tumor treatment in both gﾭroups was comparable to the 
Figure 3.  TRP-1 CD4+ T cells become cytotoxic T cells in vivo. (A) Spleens from tumor-bearing RAG/ mice treated with TRP-1 CD4+ T cells on day 7 
after tumor challenge were stained ex vivo with antibodies to CD4, V14, perforin, LAMP-1 (CD107a), and granzyme B 1 wk after adoptive cell transfer. 
Intracellular staining was performed as indicated in Materials and methods. Flow cytometry shows gated TRP-1 CD4+V14+ cells. Data represent two 
independent experiments (n = 5 mice/group).JEM VOL. 207, March 15, 2010 
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Figure 4.  Mechanism of treatment by TRP-1 CD4+ T cells. (A) Confocal microscopy of day-14 tumors, 1 wk after adoptive cell transfer with 2 × 105 
naive TRP-1 CD4+ T cells. Tumors were frozen in OCT, cut, and stained with DAPI (blue) and MHC class II (red). Samples were analyzed by confocal micros-
copy (Olympus) with a 20× oil immersion objective. Bars, 50 µm. (B) 7-d tumor-bearing MHC class II/ mice were irradiated with 5 Gy or not irradiated 
and treated with 2 × 105 naive TRP-1 CD4+ T cells. (C) 7-d tumor-bearing non-TCR Tg Tyrp1B-wRAG/ mice were irradiated with 5 Gy or not irradiated 
and treated with 2 × 105 naive TRP-1 CD4+ T cells. (D) 11-d tumor-bearing RAG/ mice were treated with naive TRP-1 CD4+ T cells or not and, in  
addition, some treated mice received one injection of 500 µg of neutralizing anti–IFN- antibodies on day 7 of ACT. Data are representative of four  
independent experiments with five to eight mice per group. (E) DC activation in lymphopenic mice after ACT with TRP-1 CD4+ T cells. Flow cytometry  
of CD11chighMHC class IIhigh and CD86high DCs from tumor-bearing RAG/ mice undergoing treatment or not. Bar graphs indicate absolute numbers  
of CD11chigh MHC class II+ CD86high cells. Values represent SEM (n = 3 mice/group; **, P < 0.05). Data are representative of four experiments.658 Naive CD4+ T cells eradicate established melanoma | Xie et al.
Figure 5.  Activation, persistence, and memory formation of TRP-1 CD4+ T cells. (A) Long-term tumor regression. Lymphopenic mice were treated 
on day 7 after tumor challenge with adoptive transfer of naive TRP-1 CD4+ T cells and followed for 270 d. (B) TRP-1 CD4+ T cells persist for long periods 
in lymphopenic mice. Error bars indicate SEM. (C) Flow cytometry of CD44 and CD62L expression on naive TRP-1 CD4+ T cells before transfer, after 1 wk  
of in vivo differentiation, and at 270 d. (D) IL-7R expression on naive (shaded) and 1-wk in vivo differentiated and 270-d persisting TRP-1 CD4+ T cells 
(solid line). (E) Phenotype of 270-d-old treated RAG/ mice. (F) Granzyme B, IFN-, and TNF expression in TRP-1 CD4+ T cells isolated on day 120 after 
treatment from tumor-free mice. Data are representative of two experiments (n = 5 mice/group).
when compared with nontreated gﾭroups (Figﾭ. 4 E). Collectively, 
these experiments sugﾭgﾭest that adoptively transferred TRP­1 
CD4+ T cells become activated on host MHC class II+ cells and 
may eradicate tumors througﾭh an IFN­–dependent pathway 
that may be linked to MHC class II expression on the tumor.
Activation, persistence, and memory formation of TRP-1 
CD4+ T cells
To determine how lymphopenia affects longﾭ­term mainte­
nance and memory formation of Th1 CD4+ T cells, we ana­
lyzed TRP­1 CD4+ T cells from mice undergﾭoingﾭ longﾭ­ 
term tumor therapy (270 d). It may be possible that   
in vivo differentiation migﾭht bestow upon T cells a sigﾭnal   
that allows them to persist and become superior antitumor   
CD4+ T cells. Therefore, we looked at longﾭ­term mainte­
nance and found that adoptively transferred TRP­1 CD4+ 
T cells can maintain tumor regﾭression and persist at rela­
tively higﾭh levels 270 d after transfer (Figﾭ. 5, A and B). We 
also looked at memory formation and activation markers 
that differentiate between effector memory T cells (TEMs) 
and central memory T cells (TCMs). CD62L and CD44 
were higﾭh and low, respectively, as expected before transfer 
of CD4+ T cells (Figﾭ. 5 C). Naive T cells were also IL­
7Rhigﾭh (Figﾭ. 5 D). After 1 wk, CD4+ T cells became acti­
vated as shown by the phenotype CD62Llow, CD44higﾭh, and 
IL­7Rlow (Figﾭ. 5, C and D). Mice were analyzed for adop­
tively transferred T cells agﾭain 270 d later. CD4+ T cells   
remained at higﾭh levels and were mostly TEM (CD62Llow JEM VOL. 207, March 15, 2010 
Article
659
transferred TRP­1 CD4+ T cells into RAG/c
/ hosts, 
which lack NK cells in addition to T, B, and NKT cells 
(Cao et al., 1995). Previously, it was shown that treatment 
of a 1­d tumor was hindered in RAG/c
/ mice (Perez­
Diez et al., 2007), and this was attributed to a lack of NK 
cells. In agﾭreement with the previous study, we found that 
tumor  therapy  was  hindered  even  when  supplemented 
with irradiation (Figﾭ. 6 A). To examine this further, we 
depleted NK cells in tumor­bearingﾭ RAG/ mice startingﾭ 
on days 0 and 7 after tumor challengﾭe, 1 d after ACT, and 
then weekly. TRP­1 CD4+ T cells were transferred into 
tumor­bearingﾭ RAG/ mice on day 8. We found that 
NK1.1 depletion (1 mgﾭ of anti­NK1.1/mouse) did not af­
fect tumor treatment in a negﾭative manner (Figﾭ. 6 B). We also 
irradiated RAG/ mice with 5 Gy. The results were similar 
to those associated with NK cell depletion (Figﾭ. 6 A). Next, 
we transferred 5 × 106 sorted NK cells into RAG/  c
/ 
mice alongﾭ with TRP­1 CD4+ T cells. Treatment was 
similar to RAG/c
/ mice with TRP­1 CD4+ T cells 
alone (Figﾭ. 6 C).
and  CD44higﾭh),  but  12%  of  CD4+  T  cells  were  TCM 
(CD62Lhigﾭh and CD44higﾭh; Figﾭ. 5 C).
To assess whether TRP­1 self­reactive T cells converted 
to T regﾭ cells over this time span, we looked at Foxp3 expres­
sion in adoptively transferred cells and found that in longﾭ­
term responder mice, Foxp3 expression remained stable at 
5–15% (Figﾭ. S3). Mice also became completely depigﾭmented 
(Figﾭ. 5 E). Lastly, gﾭranzyme B, IFN­, and TNF were evident 
in  TRP­1  CD4+  T  cells  120  d  after  transfer,  indicatingﾭ   
that they were effector T cells (Figﾭ. 5 F). Therefore, tumor­
specific CD4+ T cells differentiated in vivo can persist for longﾭ 
periods of time and appear to continue to clear antigﾭen based 
on the progﾭressive depigﾭmentation, gﾭranzyme B expression, 
and TEM phenotype. TRP­1 CD4+ TCM cells may also   
renew the TRP­1 CD4+ TEM pool over time.
NK cells are not required for tumor therapy with TRP-1 
CD4+ T cells
To determine host mechanisms that affect the activation 
and persistence of adoptively transferred CD4+ T cells, we 
Figure 6.  NK cells are not required for tumor therapy with TRP-1 CD4+ T cells. (A) Tumor-bearing RAG/ and RAG/c
/ mice were treated 
on day 7 without or with irradiation (5 Gy) and with and without ACT with 2 × 105 naive TRP-1 CD4+ T cells. Data are representative of three experiments 
(P < 0.0001). The p-value indicated is for RAG/ + TRP-1 versus RAG/c
/ + TRP-1 CD4+ T cells for both 0 and 5 Gy. (B) Tumor-bearing RAG/ mice 
received 1 mg of anti-NK1.1 antibodies weekly starting 1 d before ACT and were compared with tumor-bearing RAG/ mice receiving no treatment or  
2 × 105 naive TRP-1 CD4+ T cells. Data represent three experiments with five to eight mice per group. P = NS for RAG/ + TRP-1 versus RAG/ + TRP-1 
+ anti-NK1.1. (C) 7-d tumor-bearing RAG/ and RAG/c
/ mice received naive TRP-1 CD4+ T cells plus sorted NK cells from WT mice where indicated 
(P = NS for addition of NK cells). Data represent two independent experiments. Error bars indicate SEM. (D) Flow cytometry of NK cells (NK1.1+DX5+ cells) 
in the LNs of RAG/, RAG/ + anti-NK1.1 antibodies, and RAG/c
/ mice as indicated 3–4 wk after adoptive T cell transfer. Data are representative 
of three independent experiments (n = 2–3 mice/group).660 Naive CD4+ T cells eradicate established melanoma | Xie et al.
DISCUSSION
ACT usingﾭ a patient’s own immune cells to treat established 
cancer has been higﾭhly successful therapy agﾭainst melanoma 
(Rosenbergﾭ et al., 2008) and is increasingﾭly beingﾭ used agﾭainst 
other cancers as well (Stephan et al., 2007; Pule et al., 2008). 
ACT usingﾭ CD4+ T cells was recently attempted in a patient 
with metastatic melanoma usingﾭ NY­ESO­1–specific CD4+ 
T cells expanded in vitro in IL­7 and IL­2 (Hunder et al., 
2008).  Surprisingﾭly,  adoptive  transfer  therapy  with  CD4+  
T cells led to objective cancer regﾭression without prior vacci­
nation or lymphoconditioningﾭ. Althougﾭh this was reported 
in only one patient, the findingﾭs support the possibility of 
treatingﾭ established tumors without vaccination or radiation 
therapies that may cause extended morbidity in patients with 
prolongﾭed and severe sickness. In the prior study, epitope 
spreadingﾭ was reported as the likely cause of the enhanced 
treatment, indicatingﾭ that CD4+ T cells helped a CD8+ T cell 
response to the established tumor as shown in preclinical 
models (Marzo et al., 2000; Antony et al., 2006). In this pa­
per, we describe a CD8+ T cell– and vaccine­independent 
therapy in which in vivo differentiated Th1 CD4+ T cells 
recogﾭnize self and eradicate established tumors.
Althougﾭh we focused on a naive T cell– and a vaccine­
independent therapy, we do not advocate that vaccines are 
ineffective or that in vitro differentiation of T cells should not 
be attempted. Recently, it was shown that a tumor vaccine 
was required to enhance the immunotherapy of cancer when 
usingﾭ in vitro–activated antitumor CD8+ T cells and CD4+ 
Th cells (Overwijk et al., 2003; Antony et al., 2005). Vaccine 
independence was seen only after extreme radiation therapy 
(9 Gy) before ACT or in vitro progﾭrammingﾭ of TEM cells 
(Wrzesinski et al., 2007; Klebanoff et al., 2009). The impor­
tance of activatingﾭ CD4+ T cell help with a tumor vaccine 
has also been strengﾭthened of late. A study usingﾭ a modified 
TRP­1 vaccine could induce either tumor immunity or auto­
immunity dependingﾭ on the modification in the vaccine   
(Engﾭelhorn et al., 2006). When the modified vaccine acti­
vated  CD4+  T  cell  help  througﾭh  enhanced  processingﾭ  of 
MHC II peptides, tumor immunity was induced (Engﾭelhorn 
et al., 2006). This new strategﾭy to stimulate CD4+ T cells 
agﾭainst self emphasizes the need to understand how CD4+  
T cells become activated in vivo.
In this study, we demonstrate that naive CD4+ T cells 
transferred into lymphopenic hosts differentiated into Th1 
cytotoxic T cells expressingﾭ the hallmark gﾭenes associated 
with effector T cells—Tbet, IFN­, CXCR3, gﾭranzyme B, 
perforin, and LAMP­1—and caused the regﾭression of estab­
lished tumors without the aid of CD8+ T, B, NK, or NKT 
cells. CD4+ T cells have been shown to play a role in cancer 
immunotherapy througﾭh a multitude of mechanisms; CD4+ 
T cells can help cytotoxic CD8+ T cells eradicate tumors 
(Hungﾭ et al., 1998; Nishimura et al., 1999; Toes et al., 1999; 
Sutmuller et al., 2001; Behrens et al., 2004a,b; Antony et al., 
2005; Engﾭelhorn et al., 2006; Brandmaier et al., 2009), and 
CD4+ T cells can condition a DC througﾭh CD40L to en­
hance CD8+ CTL function (Bennett et al., 1998; Kalams and 
NK cells are required for efficient primingﾭ and activation 
of CD4+ T cells in vivo (Martín­Fontecha et al., 2004). We 
found that NK cells entered the LN readily in tumor­bearingﾭ 
RAG/ mice receivingﾭ CD4+ T cells but not in RAG/­
c
/  mice,  untreated  RAG/  mice,  or  NK­depleted 
RAG/ mice (Figﾭ. 6 D). These data sugﾭgﾭest that NK cells 
are not required for activation of naive tumor­specific CD4+ 
T cells in vivo.
c signaling on host cells is required for the proper 
activation, differentiation, and survival of naive tumor-
specific TRP-1 CD4+ T cells in vivo
We were perplexed as to why RAG/c
/ mice failed 
to control tumor immunity even when WT NK cells were 
present. TRP­1 CD4+ T cells were analyzed 1 wk after 
transfer from RAG/ and RAG/c
/ hosts. Expression 
of CD62L was low on both populations, indicatingﾭ activa­
tion in vivo (Figﾭ. 7 A). However, CD122, ICOS, and CD25 
were expressed at lower levels on TRP­1 CD4+ T cells from 
RAG/c
/ hosts when compared with TRP­1 CD4+  
T cells from RAG/ mice (Figﾭ. 7 A). Consistent with these 
findingﾭs,  IFN­  and  the  CXCR3  ligﾭand  CXCL9,  but  not 
CXCL10, were lower in the serum of RAG/c
/ hosts 
(Figﾭ. 7 B and not depicted). Surprisingﾭly, 1 wk after therapy, 
there were more TRP­1 CD4+ T cells in RAG/c
/ 
hosts than in RAG/ hosts (Figﾭ. 7 C), which is in agﾭree­
ment with recent findingﾭs by others (Guimond et al., 2009). 
We  therefore  looked  at  other  time  points  in  vivo  and 
found that TRP­1 CD4+ T cells failed to persist after 4 wk 
in RAG/c
/ lymphopenic hosts (Figﾭ. 7 C). Lookingﾭ 
at other parameters, we found that TRP­1 CD4+ T cells 
from RAG/ mice produced IFN­, but not IL­17, when 
stimulated ex vivo. However, TRP­1 CD4+ T cells from 
RAG/c
/ mice failed to produce IFN­ or IL­17 (Figﾭ. 
7 D). Because failure to produce IFN­ may be related to 
their failure to differentiate, we stained for the Th1 tran­
scription factor Tbet and found that expression was consid­
erably lower in TRP­1 CD4+ T cells from RAG/c
/ 
hosts (Figﾭ. 7 E). Further exploration showed that CD11chigﾭh 
DCs expressed less MHC class II and CD80 but similar lev­
els of CD40 in RAG/c
/ hosts when compared with 
RAG/ hosts (Figﾭ. 7 F). Lastly, it was possible that trans­
ferred TRP­1 CD4+ T cells could have converted to T regﾭ 
cells, which lead to tumor progﾭression, but that was not evi­
dent beyond 4 wk after therapy (Figﾭ. S4).
Collectively, the data sugﾭgﾭest that c sigﾭnalingﾭ on host cells 
may be required for proper activation of naive CD4+ T cells. 
This may occur througﾭh IL­12 sigﾭnals that increase class II and 
CD80 expression on host DCs (Ohteki et al., 2001, 2006; 
Terme et al., 2008). Consistent with this, MHC class II and 
CD80 were decreased in RAG/c
/ hosts receivingﾭ TRP­1 
CD4+ T cells. These experiments sugﾭgﾭest that lack of c sigﾭ­
nalingﾭ, possibly on host DC, in RAG/c
/ mice migﾭht 
hinder proper activation of adoptively transferred naive TRP­1 
CD4+ T cells, which eventually leads to their failure to sur­
vive and maintain treatment of established tumors.JEM VOL. 207, March 15, 2010 
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Figure 7.  c signaling on host DC is required for survival and differentiation of TRP-1 T cells in vivo. (A) Differential activation of TRP-1 CD4+  
T cells in RAG/ and RAG/c
/ hosts. Spleens from RAG/ or RAG/c
/ mice were isolated and stained for TRP-1 CD4+ T cells. Shown are CD62L, 
CD122, ICOS, and CD25 expression on gated TRP-1 CD4+ T cells from indicated host. (B) IFN- and CXCL9 are differentially expressed in the serum at 1 wk 
in RAG/ and RAG/c
/ hosts after TRP-1 CD4+ T cell transfer. Horizontal bars represent mean. (C) TRP-1 CD4+ T cells expand in RAG/c
/ hosts 
initially but fail to survive after 4 wk. Error bars indicate SEM. (D) Flow cytometry of IFN- and IL-17 expression in TRP-1 CD4+ T cells isolated from tumor 
bearing RAG/ and RAG/c
/ mice 4 wk after transfer. T cells were activated with PMA and ionomycin for 4 h and then fixed and permeabilized and 
stained with anti–IFN- and IL-17 antibodies. (E) Tbet expression in TRP-1 CD4+ T cells 4 wk after transfer. (F) MHC class II, CD80, and CD40 expression in 
RAG/c
/ hosts. Top flow diagram indicates CD11chigh MHC class II+ cells; bottom flow histograms show CD80 and CD40 expression on gated CD11chigh 
MHC class II+ cells. Solid line represents RAG/ mice treated with TRP-1 CD4+ T cells. Shaded histogram represents RAG/c
/ mice treated with TRP-1 
CD4+ T cells. Data are representative of three independent experiments (n = 5 mice/group).662 Naive CD4+ T cells eradicate established melanoma | Xie et al.
T cells, which is not dependent on NK cells. RAG/c
/ 
mice express low levels of MHC class II and CD80 on CD­
11chigﾭh cells, both of which may be needed to properly activate 
CD4+ T cells in vivo. The availability of MHC class II on APC 
has already been shown to be critical in regﾭulatingﾭ the homeo­
static proliferation of CD4+ T cells (Kassiotis et al., 2003). 
Therefore, removingﾭ DC cells by higﾭh­intensity lymphode­
pletingﾭ regﾭimens may harm ACT with CD4+ T cells. As seen 
in other studies, addingﾭ these cells back with lymphodepletingﾭ 
regﾭimens may enhance immunotherapy (Dubsky et al., 2007; 
Palucka et al., 2007; Banchereau et al., 2009).
c sigﾭnalingﾭ is part of the IL­2 cytokine family, which in­
cludes IL­4, IL­7, IL­9, IL­15, and IL­21. Increased IL­7 and 
IL­15 levels in the host have been shown in the clinic and in 
animal models to be the mechanisms by which lymphodeplet­
ingﾭ  regﾭimens  enhance  adoptive  immunotherapy  (Gattinoni   
et al., 2005a; Dudley et al., 2008; Guimond et al., 2009). How­
ever, it has not been shown in a reciprocal manner that the 
host needs c sigﾭnalingﾭ for efficient activation of tumor­specific 
T cells. We observed that with loss of c, CD4+ T cell differ­
entiation and survival were diminished by wk 4 after transfer. 
In RAG/ c
+ hosts, we saw expansion and survival of CD4+ 
T cells past 4 wk. We also found higﾭher expression of 
MHC class II on CD11chigﾭhCD86higﾭh DC and the Th1 tran­
scription factor Tbet in TRP­1 CD4+ T cells isolated from 
RAG/ mice when compared with TRP­1 CD4+ T cells 
from RAG/c
/ mice. Our results differ from those in a 
recent study showingﾭ that c sigﾭnalingﾭ on DC reduces CD4+ 
T cell homeostatic proliferation in vivo (Guimond et al., 2009). 
We found that TRP­1 CD4+ T cells expand initially at 1 wk 
after adoptive cell transfer but fail to survive in RAG/c
/ 
hosts once tumor progﾭresses, which is usually 4 wk or later. 
Surprisingﾭly, even thougﾭh there were more tumor­specific T 
cells in RAG/c
/ hosts, it was not enougﾭh to clear tumor. 
It may be possible that strongﾭ (self­reactive) TCR activation is 
a prerequisite for survival for self­reactive TRP­1 CD4+ T 
cells because the previous study used polyclonal CD4+ T cells 
or antigﾭen­specific CD4+ T cells that do not recogﾭnize an an­
tigﾭen in the host (Guimond et al., 2009). This strongﾭ activation 
(indicated by CD5 expression on TRP­1 CD4+ T cells) may 
come from increased expression of CD80 and MHC class II 
on DC that requires c for their activation to become sensitive 
to and produce IL­12, which is paramount for Th1 primingﾭ in 
vivo (Ohteki et al., 2001, 2006; Terme et al., 2008). Duringﾭ in 
vivo differentiation, TRP­1 CD4+ T cells expressed higﾭh lev­
els of IL12R1 and IL­27R duringﾭ in vivo differentiation, 
which are required for primingﾭ, and IL­23R, which may be 
important  for  Th1  memory  formation.  The  strongﾭ  up­ 
regﾭulation of Stat4 in TRP­1 T cells in vivo shows that IL­12 
and/or IL­23 sigﾭnals are drivingﾭ their activation, as indicated 
by higﾭh IFN­ production and IL­22, respectively. This is fur­
ther supported by lack of IFN­ and Tbet expression in TRP­
1 CD4+ T cells isolated from RAG/c
/ hosts 4 wk after 
transfer in addition to lack of IFN­ and CXCL9, but not 
CXCL10, in the serum at 1 wk in RAG/c
/ hosts. There­
fore, it appears that lack of proper DC activation leads to low 
Walker, 1998; Ridgﾭe et al., 1998; Diehl et al., 1999), but the 
mechanisms by which CD4+ T cells cause eradication of es­
tablished tumors by themselves are still unknown.
Previously it was shown that CD4+ T cells could prevent 
the gﾭrowth of tumors by antiangﾭiogﾭenesis througﾭh the activa­
tion of IFN­R on nonhematopoietic cells. However, this 
action was not shown for largﾭe vascularized tumors in a treat­
ment and adoptive cell transfer model and it was not clear 
whether CD8+ T cells were involved (Qin and Blankenstein, 
2000). Rejection of small tumors was also shown to be an in­
direct process througﾭh IFN­–dependent activation of mac­
rophagﾭes or by eosinophils and NK cells (Hungﾭ et al., 1998; 
Corthay et al., 2005). We noted higﾭh levels of CCL11 in the 
serum duringﾭ treatment and CCL24 expression by TRP­1 
CD4+ T cells, which are known to recruit eosinophils, so 
their  role  cannot  be  excluded.  Indirect  effects  of  CD4+  
T cells have also been noted in a study usingﾭ Tgﾭ Marylyn 
CD4+ T cells, which recogﾭnize the male antigﾭen H­Y. MHC 
class II tumors were amenable to treatment and this was at­
tributed to NK cells (Perez­Diez et al., 2007). In this paper, 
we do not find a role for NK cells in this model.
Not surprisingﾭly, with adoptive cell transfer therapies usingﾭ 
in vitro differentiated CD4+ T cells to treat largﾭe vascularized 
tumors,  IFN­R/  mice  were  shown  not  to  respond  to 
treatment (Muranski et al., 2008), and anti–IFN­ diminished 
the antitumor effect (Nishimura et al., 1999; Muranski et al., 
2008). However, IFN­/ mice were able to respond to 
treatment with in vitro differentiated CD4+ T cells, indicatingﾭ 
that the innate source of IFN­ (NK cells) was not needed 
(Qin and Blankenstein, 2000; Muranski et al., 2008). Because 
we saw increased MHC class II expression in the tumor mi­
croenvironment, it is possible that IFN­ from CD4+ T cells 
may be needed to increase MHC class II expression on tumor 
cells, which allows a direct interaction between T cells and 
cancerous cells to occur (Quezada et al., 2010). Direct killingﾭ 
of tumors is possible, as indicated by higﾭh gﾭranzyme B expres­
sion by TRP­1 CD4+ T cells on gﾭene microarray and expres­
sion of perforin, gﾭranzyme B, and LAMP­1 in TRP­1 CD4+ 
T cells isolated from the spleen. IFN­ may be workingﾭ indi­
rectly at a local level througﾭh macrophagﾭes expressingﾭ NO, 
TNF, ROS, and NKG2D receptors (Kahn et al., 1991; Raulet 
and Guerra, 2009). IFN­ released by differentiated CD4+ T 
cells may be so extremely higﾭh in the tumor microenviron­
ment that the tumor vasculature expressingﾭ IFN­ receptors 
undergﾭoes anti­angﾭiogﾭenesis. The presence of specific disease, 
indicated  by  depigﾭmentation  and  uveitis  (Muranski  et  al., 
2008),  supports  the  theory  of  a  direct  killingﾭ  mechanism 
agﾭainst MHC class II+ cells. Inflammatory monocytes in the 
tumor microenvironment may also play an indirect role in the 
process. Another unappreciated role of IFN­ may be to in­
duce the chemokines CXCL9 and CXCL10 (Luster et al., 
1985), which may be required to attract CXCR3+ antitumor 
CD4+ T cells into the tumor site. Most importantly, all of 
these mechanisms may not be mutually exclusive.
Why then does tumor therapy fail in RAG/c
/ mice? 
CD4+ T cells need to become properly activated cytotoxic   JEM VOL. 207, March 15, 2010 
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et al., 2007). It can also break tolerance to a poorly immuno­
gﾭenic tumor (Wilcox et al., 2002). ICOS is beingﾭ considered 
as another immunotherapy candidate (Paulos, C. and June, C., 
personal communication). These therapies could be com­
bined with ACT in the future.
In this study, we focused on naive CD4+ T cells, which 
differentiate properly in their natural state and become longﾭ­
lived memory T cells. This idea was also demonstrated in an­
other tumor model that involved activation of naive T cells 
via forced LIGHT expression in the tumor microenviron­
ment (Yu et al., 2004). Althougﾭh forced expression of LIGHT 
in human tumors may not be a clinical reality, this led to a 
profound tumor rejection indicatingﾭ the importance of acti­
vatingﾭ naive T cells in their natural state.
How do you obtain naive T cells from humans? TCR 
transduction of naive T cells with CD4+ MHC class II tumor­
specific TCRs could be attempted in humans, as previously 
achieved with MHC class I tumor­specific TCRs (Morgﾭan   
et al., 2006; Hinrichs et al., 2009). It may be possible to trans­
fer naive tumor­specific CD4+ T cells into hosts precondi­
tioned with noninvasive cytokine therapies that do not cause 
harmful side effects. Transduction of higﾭh avidity TCRs to 
tumor antigﾭens into naive or cord PBL is feasible and may be 
augﾭmented by higﾭh doses of IL­7 or IL­15 administration 
plus anti­CTLA or anti­41BB therapy.
How do you obtain nontolerant higﾭhly reactive TCRs as 
seen in this paper? Mouse TCRs reactive agﾭainst human can­
cer antigﾭens can be transfected into human T cells usingﾭ gﾭene 
therapy (Johnson et al., 2009). Human HLA Tgﾭ mice can be 
immunized with human cancer antigﾭens to gﾭenerate higﾭhly 
tumor­reactive TCRs, which can then be used in the immuno­
therapy of cancer in humans.
In summary, TRP­1 Tgﾭ mice represent a new ACT im­
munotherapy model for the study of ways to induce potent 
antitumor immunity agﾭainst established melanoma without the 
need for cytotoxic CD8+ T cells or a vaccine. Understandingﾭ 
the mechanisms of tumor regﾭression in mice with lymphope­
nia may allow the development of new therapies that work in 
the absence of chemotherapy and radiation. These data sugﾭgﾭest 
a new role for CD4+ T cells as cytotoxic T cells.
MATERIALS AND METHODS
Mice.  Tyrp1B-wRAG/  TRP­1­specific  CD4+  TCR  Tgﾭ  mice  (B6.Cgﾭ­
Rag1tm1Mom Tyrp1B-w Tgﾭ(Tcra,Tcrb)9Rest/J; deposited at The Jackson Labora­
tory) and WT Tyrp1+/+ TRP­1­specific CD4+ TCR Tgﾭ mice were created 
by P.A. Antony and K. Irvine at the National Cancer Institute (Bethesda, 
MD; Muranski et al., 2008). Recombination­activatingﾭ gﾭene 1/ (Rag1tm1Mom) 
mice, Foxp3sf, C57BL/6 WT, and MHC class II/ were purchased from 
The Jackson Laboratory. RAG/c
/ mice were purchased from Taconic 
(Cao et al., 1995). Foxp3sf mice were crossed with Tyrp1+/+ TRP­1­specific 
CD4+ TCR Tgﾭ mice to gﾭenerate Tyrp1+/+ TRP­1­specific CD4+ TCR 
Foxp3sf Tgﾭ mice. All mice were used in accordance with gﾭuidelines from the 
University of Maryland Institutional Animal Care and Use Committee. All 
experiments were conducted with the approval of the Animal Use and Care 
Committees  of  the  National  Cancer  Institute,  Johns  Hopkins  University 
School of Medicine, and the University of Maryland School of Medicine.
Tumor lines and measurement. B16.F10 (H­2b), hereafter called B16, is 
a TRP­1+ spontaneous murine melanoma that was obtained from ATCC 
expression of MHC class II and CD80, which subsequently 
leads  to  inappropriate  activation  of  naive  TRP­1  CD4+  
T cells in RAG/c
/ hosts. Loss of IFN­ expression by 
CD4+ T cells possibly leads to loss of CXCL9 expression in 
the tissues, and this may lead to failure of recruitment of anti­
tumor CXCR3+ CD4+ T cells to the tumor site. This pattern 
of recruitment may be similar to the process that occurs dur­
ingﾭ nephritis or disease of the eye duringﾭ herpes simplex virus 
type 1 infection, which requires CXCL9, but not CXCL10, 
for recruitment of CXCR3+ T cells into the tissues (Wuest   
et al., 2006; Menke et al., 2008).
Why seek to understand how TRP­1 CD4+ T cells are 
activated in vivo? More intense ablation may remove DCs 
that provide the secondary sigﾭnals (such as IL­12 or possibly 
IL­23) that are needed to properly differentiate CD4+ T cells 
in vivo into longﾭ­lived memory cells, which is similar to IL­2 
for CD8+ T cells (Williams et al., 2006). Less space may be the 
Achilles’ heel of intense lymphodepletion when usingﾭ CD4+ 
T cells. This may indicate that CD4+ T cells are not receivingﾭ 
the proper sigﾭnals initially for longﾭ­lived survival. In mice ir­
radiated with 9 Gy and humans receivingﾭ 12 Gy lymphode­
pletingﾭ regﾭimens, IL­2 administration was needed to augﾭment 
ACT. Transfer of naive T cells has not yet been accomplished 
in these settingﾭs. These cells may require administration of 
DC for support (Steinman and Banchereau, 2007).
How can this environment be obtained without lympho­
depletingﾭ chemotherapy or irradiation? Cytokines (such as   
IL­7 and IL­15) found in patients receivingﾭ higﾭh­dose radia­
tion therapy and irradiated WT and RAG/ mice may be 
used to mimic lymphopenia in a WT host (Gattinoni et al., 
2005a; Zhangﾭ et al., 2005; Guimond et al., 2009; Pellegﾭrini   
et al., 2009). In humans, IL­7 has shown strongﾭ promise in   
recent years, and longﾭ administration has been shown to 
release the inhibitory networks that suppress antitumor im­
munity (Pellegﾭrini et al., 2009). Cytokine/antibody immune 
complexes to IL­2, IL­7, or IL­15 may offer another way to 
mimic lymphopenia, as a much lower amount of cytokines   
is  needed  to  enhance  proliferation  of  naive  and  memory   
phenotype  T  cells  in  vivo  (Boyman  et  al.,  2006,  2008;   
Rubinstein et al., 2006; Cho et al., 2007). Lymphopenia­
  induced activation of CD4+ T cells itself may progﾭram these 
cells to become less prone to tolerance induction seen in 
other systems usingﾭ CD4+ T cells (Sotomayor et al., 1999), 
and we are currently exploringﾭ this.
Administration  of  antibodies  agﾭainst  costimulatory  and 
inhibitory molecules is another method to enhance antitumor 
immunity. We saw higﾭh expression of CTLA­4 and 41BB   
on TRP­1 CD4+ T cells. Anti–CTLA­4 therapy is beingﾭ 
used in clinical trials and has been shown to enhance adoptive 
cell therapies already with CD8+ T cells and donor lympho­
cyte infusions by inhibitingﾭ T regﾭ cells and enhancingﾭ activa­
tion of non–T regﾭ cells (Quezada et al., 2006, 2008; Pegﾭgﾭs   
et al., 2009). With tumor­specific TRP­1 CD4+ T cells, this 
enhances therapy considerably in WT and lymphopenic hosts 
(Quezada et al., 2010). Stimulation of 41BB also enhances 
immunotherapy usingﾭ T cells coexpressingﾭ 41BBL (Stephan 664 Naive CD4+ T cells eradicate established melanoma | Xie et al.
complementary RNA was purified usingﾭ RNeasy micro kit (QIAGEN) and 
followed by quantification of both concentrations of complementary RNA 
and dye labeled. RNA spike­in controls (Agﾭilent Technologﾭies) were added 
to RNA samples before amplification and labelingﾭ accordingﾭ to the manu­
facturer’s protocol. The entire amount of each sample labeled with Cy3 or 
Cy5 was mixed with control targﾭets (Agﾭilent Technologﾭies). Fragﾭmentation 
was performed by incubatingﾭ at 60°C for 30 min and stopped by addingﾭ an 
equal volume of 2× GE Hi­RPM hybridization buffer (Agﾭilent Technolo­
gﾭies). Agﾭilent 4X44K whole mouse gﾭenome array (G4122F) with 41534 
unique probes was used. Fragﾭmented targﾭets were added onto a microarray, 
assembled into a hybridization chamber (Agﾭilent Technologﾭies), and hybrid­
ized at 60°C for 17 h in a hybridization oven with rotation. Hybridized   
microarrays were washed and dried accordingﾭ to the Agﾭilent microarray   
processingﾭ protocol. Microarrays were scanned usingﾭ an Agﾭilent G2505B 
Scanner controlled by Agﾭilent Scan Control 7.0 software. Data were ex­
tracted with Agﾭilent Feature Extraction 9.1 software. Differentially expressed 
targﾭets were identified usingﾭ the processed data and the logﾭ ratio gﾭenerated 
by the software. Only values of twofold or higﾭher were reported. Heat maps 
were hand gﾭenerated from the gﾭene lists. The GEO microarray data acces­
sion no. is GSE19904.
Measurement  of  serum  cytokines  and  chemokines.  Serum  was   
collected via tail vein usingﾭ serum collection tubes (BD). Serum was ana­
lyzed by MILLIPLEX 32­Plex assay (University of Maryland, Baltimore, 
Cytokine Core Laboratory, and Millipore).
Statistics. An unpaired Student’s t test was used to compare the differences 
between cytokines and chemokines as indicated. Tumor curves were com­
pared usingﾭ a two­way ANOVA with nonrepeated measures. P­values of 
≤0.05 were considered sigﾭnificant. PRISM 5.0b software was used to analyze 
the data (GraphPad Software, Inc.).
Online supplemental material. Figﾭ. S1 shows the phenotype of TRP­1 
Tgﾭ WT, Foxp3sf, and tyrp1B-w mice. Figﾭ. S1 also shows that TRP­1 CD4+ 
cells are activated in WT mice but not in tyrp1B-w mice. Foxp3 expression in 
naive TRP­1 CD4+ T cells from tyrp1B-w RAG/ mice is shown. Lastly, 
tumor infiltration by TRP­1 CD4+ T cells is shown by flow cytometry.   
Figﾭ. S2 shows accumulation of inflammatory monocytes in the spleen, LN, 
and tumor after adoptive transfer of TRP­1 CD4+ T cells into tumor­bearingﾭ 
lymphopenic mice. Figﾭ. S3 shows stable expression of Foxp3 in TRP­1 
CD4+ T cells after tumor treatment. Figﾭ. S4 shows that TRP­1 CD4+ T cells 
do not convert to Foxp3+ cells in RAG/c
/ tumor­bearingﾭ hosts duringﾭ 
tumor progﾭression. Online supplemental material is available at http://www 
.jem.orgﾭ/cgﾭi/content/full/jem.20091921/DC1.
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and maintained in culture media as previously described (Antony et al., 
2006). Tumors were injected subcutaneously at 2 × 105 cells/mouse. Tumors 
are measured blindly with digﾭital calipers. The perpendicular diameters are 
determined and multiplied to gﾭenerate the area in millimeters squared as 
previously described (Antony et al., 2006).
Sorting and adoptive cell transfer. TRP­1 CD4+ T cells were sorted from 
spleens of donor Tyrp1B-wRAG­1/ TRP­1–specific Tgﾭ male mice. Spleens 
were harvested and made into singﾭle­cell suspensions. Cells were made devoid 
of red blood cells by ACK lysis. Subsequently, cells were counted and enriched 
for CD4+ T cells by magﾭnetic bead sortingﾭ usingﾭ a CD4+ T cell enrichment kit 
from Miltenyi Biotec. Enriched CD4+ T cells were counted and resuspended 
in PBS and used in adoptive transfer studies (2 × 105 cells/mouse). NK cells 
were isolated from WT mice usingﾭ NK cell sortingﾭ kits from Miltenyi Biotec. 
When indicated, 5 × 106 NK cells were transferred on the same day as TRP­1–
  specific T cells. Open­repertoire CD4+CD25 T cells from WT mice were 
sorted as previously described (Antony et al., 2006). Mice were irradiated as 
previously described (Wrzesinski et al., 2007).
Depleting antibodies. Anti–IFN­ (XMG1.2, NA/LE) and anti­NK1.1 
(NA/LE, PK136) were purchased from BD.
Flow cytometry. Anti­CD4 (RM4­5), anti­CD25 (PC61), anti­CD122 
(TM­­1), anti­V14 (14–2), anti­NK1.1 (PK136), anti­ICOS (7E.17G9), 
anti­CD44 (IM7), anti­CD62L (MEL­14), anti­CD11c (HL3), anti­CD86 
(GL1), anti–MHC class II (AF6­120.1), anti–IL­17 (TC11­18H10), anti–
IFN­  (XMG1.2),  anti­TNF  (MP6­XT22),  anti­CD49b  (DX5),  and 
CD11b  (M1/70)  were  obtained  from  BD.  Anti–IL­7R  (SB/199),   
anti­CXCR3  (CXCR3­173),  anti­Foxp3  (FJK­16s),  anti­Tbet  (4B10), 
anti–MHC class II (I­A/I­E; M5/114.15.2), anti–GR­1 (RB6­8C5), anti­
perforin  (eBioOMAK­D),  anti­NKp46  (29A1.4),  anti­LAMP­1  (1D4B), 
anti–gﾭranzyme  B  (16G6),  and  anti­NKG2D  (CX5)  were  obtained  from 
eBioscience. All flow cytometry scales are logﾭ scales, if not otherwise speci­
fied.  Intracellular  stainingﾭ  for  cytokines  was  done  with  the  Cytofix/
Cytoperm  intracellular  stainingﾭ  kit  (BD).  For  gﾭranzyme  B,  Foxp3,  and 
perforin, the Foxp3 stainingﾭ buffer set was used as recommended by 
eBioscience. All samples were run on a FACSCalibur (BD; Department of 
Surgﾭery, University of Maryland School of Medicine) and analyzed by   
FlowJo Software (Tree Star, Inc.).
Confocal microscopy. Confocal microscopy was done as previously de­
scribed (Quezada et al., 2008) except that slides were imagﾭed on an LSM 
(Olympus) with a 20× oil immersion objective. In brief, tumor was frozen 
in OCT solution (Sakura). 8­µm sections were cut with a microcryotome 
(Leica), fixed for 10 min in cold acetone, allowed to air dry, hydrated with 
PBS for 5 min, and then blocked with PBS with 2% FCS, 50 µgﾭ/ml 24G2 
antibodies, and 5% rat, hamster, and mouse serum for 15 min. Slides were 
stained overnigﾭht with anti–MHC class II APC and DAPI, washed, and 
mounted. Samples were scanned on an inverted confocal microscope (LSM; 
University of Maryland Greenebaum Cancer Center) under a 20× oil im­
mersion objective. Imagﾭes were analyzed with Imagﾭe J64 software (National 
Institutes of Health).
Gene microarrays. RNA was isolated from FACS­sorted CD4+ T cells 
from LN and spleens of tumor­bearingﾭ RAG/ mice undergﾭoingﾭ treatment 
with TRP­1 CD4+ T cells. RNA was isolated with RNA isolation kits 
(QIAGEN). Sample amplification and labelingﾭ procedures were performed 
usingﾭ  a  Low  RNA  Input  Fluorescent  Linear  Amplification  kit  (Agﾭilent 
Technologﾭies). In brief, 400 ngﾭ of total RNA was used as startingﾭ material 
base on available yield of RNA isolation but was kept at the same amount of 
input in each experiment. Total RNA was reverse transcribed into first­
strand and second­strand complementary DNA by MMLV­RT usingﾭ an 
oligﾭo­dT primer that incorporates a T7 promoter sequence. The comple­
mentary DNA was then used as a template for in vitro transcription in the 
presence of T7 RNA polymerase and cyanine­labeled CTPs. The labeled JEM VOL. 207, March 15, 2010 
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